Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC

Phase 4 Study of Peg-interferon Plus Ribavirin Therapy for Prevention of Hepatocellular Carcinoma

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00375661

Enrollment

100

Registered

2006-09-13

Start date

2006-09-30

Completion date

2013-03-31

Last updated

2015-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C, Chronic

Keywords

hepatocellular carcinoma

Brief summary

The purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (HCC) in patients who had the curative resection of primary HCC.

Interventions

DRUGinterferon-alfa-2b and ribavirin

Interferon, pnce per week plus daily ribavirin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

25 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of Hepatocellular carcinoma due to Chronic Hepatitis C Virus Infection. * Must be treated with curative treatment for primary tumor using either surgical resection or radiofrequency ablation therapy

Exclusion criteria

* No recurrence of hepatocellular carcinoma 3 months after the primary treatment * Renal dysfunction

Design outcomes

Primary

Measure	Time frame
Incidence of adverse effect of interferon	During the treatment period

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026